Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. executive Henry Lee Chan reported an automated sale of American Depositary Shares to satisfy tax obligations tied to restricted share unit vesting. He sold 590 American Depositary Shares at $265.975 each, representing 13 ordinary shares per ADS, and now directly holds 338,884 Ordinary Shares.
BeOne Medicines Ltd. executive Wang Lai reported a small mandatory share sale tied to equity compensation. On the date shown, he sold 1,169 American Depositary Shares at a weighted average price of $265.3857 per ADS to satisfy tax withholding on a vesting restricted share unit award, rather than as a discretionary trade. Each ADS represents 13 ordinary shares. After these transactions, he continues to hold 1,694,888 ordinary shares directly, while additional ordinary shares are held indirectly through Wang Holdings LLC and an employee RMB share participation plan, for which he disclaims beneficial ownership except for any pecuniary interest.
ONC proposes the sale of 590 ADSs under a registered plan vesting on 06/15/2026. The Form 144 lists the security as ADS and notes the disposition method as "Restricted Stock Vesting Under a Registered Plan." The filing also shows recent ADS dispositions by Chan Lee on 06/11/2026 (428 ADS, $110,267.78) and 06/08/2026 (871 ADS, $235,539.13), plus two trades of 332 ADS each on 05/13/2026 and 04/08/2026 with proceeds of $103,159.04 and $103,447.88.
ONC notice under Rule 144 reporting proposed sales of ADS and recent dispositions by a named holder. The filing lists an intended sale entry for ADS with a 06/15/2026 vesting/registered‑plan notation and two reported dispositions by Lai Wang on 06/08/2026 and 06/11/2026.
The record shows quantities reported next to those dates (1367 and 756) and references NASDAQ. This filing is administrative notice of resale under Rule 144; it does not state price or proceeds.
ONC submitted a Rule 144 notice reporting proposed sales of American Depositary Shares (ADS) by an affiliate. The filing lists a Restricted Stock Vesting Under a Registered Plan for 1,357 ADS on 06/15/2026 and two prior ADS dispositions by Xiaobin Wu on 06/11/2026 (626 ADS) and 06/08/2026 (1,484 ADS), with dollar amounts shown in the excerpt.
Form 144 filing reports ADS dispositions by an affiliate of the issuer. The notice lists ADS as the security type with dates in June 2026 and specific recent dispositions: 1,949 ADS for $501,354.72 on 06/11/2026 and 4,940 ADS for $1,336,547.63 on 06/08/2026. The filing also references a restricted stock vesting under a registered plan dated 06/15/2026.
BeOne Medicines Ltd. principal accounting officer Titus B. Ball reported a mix of compensation-related share activity and tax-driven sales. On June 11, 2026, he had 169 American Depositary Shares sold in open-market transactions, with prices around $256–$258 per ADS. A footnote explains these sales were executed under a mandatory tax withholding provision tied to the vesting of an earlier restricted share unit award, rather than discretionary selling. The same day, he received a grant of 31,213 Ordinary Shares underlying restricted share units at no purchase price, bringing his direct holdings to 99,645 Ordinary Shares. These restricted share units vest in four equal annual installments starting on June 11, 2026, with potential accelerated vesting upon certain termination events. Each ADS represents 13 Ordinary Shares, connecting the ADS activity to the underlying ordinary share structure.
BeOne Medicines Ltd. executive Wang Lai reported equity compensation grants and a small tax‑related share sale. He received 118,625 Ordinary Shares as a restricted share unit award and 229,775 share options with a $20.81 exercise price, both vesting over four years, subject to continued service and potential accelerated vesting upon certain termination events.
A total of 756 American Depositary Shares, each representing 13 Ordinary Shares, were sold at a weighted average price of about $261.00 per ADS under a mandatory tax withholding provision tied to a prior restricted share unit vesting, rather than a discretionary open‑market sale. Following these transactions, he directly holds 1,710,085 Ordinary Shares and 229,775 options, while additional Ordinary and RMB Shares are held by entities such as Wang Holdings LLC and the RMB Shares Employee Participation Plan, over which he disclaims Section 16 beneficial ownership and generally lacks voting or dispositive power.
BeOne Medicines Ltd. Chief Financial Officer Aaron Rosenberg reported routine equity compensation activity and a small tax-related sale. He sold 631 American Depositary Shares in an open-market transaction at a weighted average price of $257.7441 per ADS, executed pursuant to a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each ADS represents 13 Ordinary Shares.
Rosenberg also received 71,175 Ordinary Shares as a grant or award, bringing his direct Ordinary Share holdings to 397,891 shares. In addition, he was granted options over 137,865 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. Both the new restricted share units and options vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder vesting in equal installments thereafter, subject to continued service and potential accelerated vesting upon certain termination events.
BeOne Medicines President and COO Wu Xiaobin reported new equity awards and a small tax-related sale. He received 118,625 Ordinary Shares through a restricted share unit grant and 229,775 share options with a $20.81 exercise price, both as compensation.
He also sold 626 American Depositary Shares at a weighted average price of $261.2017 per ADS to satisfy mandatory tax withholding tied to earlier restricted share unit vesting. After these awards, he directly holds 1,308,161 Ordinary Shares and 229,775 share options, and indirectly 4,000 ADS held by his wife.